Open Access Open Access  Restricted Access Subscription Access

An Objectives, Indications, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interactions, Contra Indications, Toxicity and Health Care Team Outcomes of Ramipril Drug

Srinivas G., Ramanjaneyulu D. V., Satyanarayana Murthy S., Muralinath E., Guruprasad M., Hari Kiran M., Shaik Mahabooob Basha, Kundara Giridhar Reddy, Kasireddy Gauthami, Mopoori Kalyan, Sai Charan B., Sainath Reddy T., Ramesh U., Rahul P., Rajitha V.

Abstract


An angiotensin-converting enzyme (ACE) inhibitor called ramipril is used to treat hypertension and slow the progression of heart failure in patients, particularly those who have had a myocardial infarction in the past. In patients over 55 who are at high risk for atherosclerotic disease and severe adverse cardiac events, this medicine is also designated for lowering the risk of myocardial infarction, stroke, and death. Ramipril reduces sympathetic activity and the kidneys' ability to reabsorb water and salt by blocking the formation of angiotensin II. Blood pressure is lowered by the vasodilation that results.

 

The indications, mechanism of action, pharmacokinetics, dosage, and administration of ramipril are reviewed in this activity. Additionally, it draws attention to important side effects, contraindications, monitoring guidelines, and drug interactions. This article encourages the treatment of cardiovascular disease and hypertension by raising doctors' awareness of these factors.


Full Text:

PDF

References


Anderson, V. R., Perry, C. M., & Robinson, D. M. (2006). Ramipril: A review of its use in preventing cardiovascular outcomes in high-risk patients. American Journal of Cardiovascular Drugs, 6(6), 417–432.

Warner, G. T., & Perry, C. M. (2003). Spotlight on ramipril in the prevention of cardiovascular outcomes. American Journal of Cardiovascular Drugs, 3(2), 113–116.

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895–e1032.

O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., Granger, C. B., Krumholz, H. M., Linderbaum, J. A., Morrow, D. A., Newby, L. K., Ornato, J. P., Ou, N., Radford, M. J., Tamis-Holland, J. E., ... Zhao, D. X. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61(4), e78–e140.

Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., Levine, G. N., Liebson, P. R., Mukherjee, D., Peterson, E. D., Sabatine, M. S., Smalling, R. W., & Zieman, S. J. (2014). 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 130(25), e344–e426.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. (2021). KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International, 99(3S), S1–S87.

Fountain, J. H., Kaur, J., & Lappin, S. L. (2023). Physiology, renin angiotensin system. In StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing.

Thatcher, S. E. (2017). A brief introduction into the renin-angiotensin-aldosterone system: New and old techniques. Methods in Molecular Biology, 1614, 1–19.

Borghi, C., Cicero, A. F., Agnoletti, D., & Fiorini, G. (2023). Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences? European Journal of Internal Medicine, 110, 10–15.

Hermann, R., Gundlach, K., & Seiler, D. (2021). Mechanistic considerations about an unexpected ramipril drug-drug interaction in the development of a triple fixed-dose combination product containing ramipril, amlodipine, and atorvastatin. Clinical Pharmacology in Drug Development, 10(11), 1307–1315.

Soboleva, M. S., & Loskutova, E. E. (2020). Analysis of preferences in the use of fixed-dose combinations of antihypertensive drugs in the regions of the Far-Eastern Federal District. ClinicoEconomics and Outcomes Research, 12, 265–272.

Fischer, K., & Diec, S. (2021). Once- versus twice-daily angiotensin-converting enzyme inhibitors for blood pressure control in adult patients with hypertension. Cureus, 13(8), e17331.

Buawangpong, N., Teekachunhatean, S., & Koonrungsesomboon, N. (2020). Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis. Pharmacology Research Perspectives, 8(5), e00644.

Hallberg, P., Persson, M., Axelsson, T., Cavalli, M., Norling, P., Johansson, H. E., Yue, Q. Y., Magnusson, P. K., Wadelius, C., Eriksson, N., & Wadelius, M. (2017). Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: A genome-wide association study in a Swedish population. Pharmacogenomics, 18(3), 201–213.

Mu, G., Xiang, Q., Zhang, Z., Liu, C., Zhang, H., Liu, Z., Pang, X., Jiang, J., Xie, Q., Zhou, S., Wang, Z., Hu, K., Wang, Z., Jiang, S., Qin, X., & Cui, Y. (2020). PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: A nested case-control genome-wide study. Pharmacogenomics, 21(9), 601–614.

Krause, A. J., Patel, N. B., & Morgan, J. (2019). An unusual presentation of ACE inhibitor-induced visceral angioedema. BMJ Case Reports, 12(9).

Hobbs, S. D., Claridge, M. W., Wilmink, A. B., Adam, D. J., Thomas, M. E., & Bradbury, A. W. (2008). Effect of ramipril on renal function in patients with intermittent claudication. Vascular Health and Risk Management, 4(2), 471–475.

Horowitz, N., Molnar, M., Levy, Y., & Pollack, S. (2005). Ramipril-induced agranulocytosis confirmed by a lymphocyte cytotoxicity test. American Journal of the Medical Sciences, 329(1), 52–53.


Refbacks

  • There are currently no refbacks.